Skip to main content
. 2023 Nov 13;14:1212813. doi: 10.3389/fphar.2023.1212813

TABLE 3.

Comparison of randomized and non-randomized trials.

Characteristic Trial phase
Phase 3 (n = 18) Phase 2 (n = 72) Phase 1 (n = 12)
Blinding (%) 6 (33.3) 3 (4.2) 0 (0)
No. of participants, median (Range) 276 (200–556) 47 (14–206) 108.5 (23–242)
Multicenter (%) 15 (83.3) 24 (33.3) 7 (58.3)
Randomization (%) 18 (100) 18 (25.0) 0 (0)
Primary outcome as safety (%) 0 (0) 4 (5.6) 7 (58.3)
Primary outcome as OS(%) 5 (27.8) 2 (2.8) 0 (0)

Abbreviation: OS, overall survival.